Search research articles
Contact Us
Filters
Showing results (71-80 of 123) with videos related to
Page
of 13
Sort By:
The AAPS Journal
|
May 16, 2025
Publisher Correction: Simultaneous Estimation of fm and FG Values Directly from Clinical Drug-Drug Interaction Study Data
Yumi Cleary, Nicolo Milani, Kayode Ogungbenro, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
December 13, 2005
Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial
Marylore Chenel, Kayode Ogungbenro, Vincent Duval, et al.
Pharmaceutical Research
|
November 27, 2014
Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects
Thierry Wendling, Kayode Ogungbenro, Etienne Pigeolet, et al.
The AAPS Journal
|
November 6, 2015
Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data
Thierry Wendling, Nikolaos Tsamandouras, Swati Dumitras, et al.
The AAPS Journal
|
December 16, 2015
Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions
Alison Margolskee, Adam S Darwich, Aleksandra Galetin, et al.
The AAPS Journal
|
April 29, 2025
Simultaneous Estimation of fm and F<sub>G</sub> Values Directly from Clinical Drug-Drug Interaction Study Data
Yumi Cleary, Nicolo Milani, Kayode Ogungbenro, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
March 22, 2006
Optimal design for multivariate response pharmacokinetic models
Ivelina Gueorguieva, Leon Aarons, Kayode Ogungbenro, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
March 5, 2021
Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed
Aurélie Lombard, Hitesh Mistry, Sonya C Chapman, et al.
British Journal of Clinical Pharmacology
|
August 24, 2017
Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials
Parul Patel, Eleanor Howgate, Paul Martin, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
December 3, 2014
Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model
Andrés Olivares-Morales, Yoshiteru Kamiyama, Adam S Darwich, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 123) with videos related to
Sort By:
Page
of 13
The AAPS Journal
|
May 16, 2025
Publisher Correction: Simultaneous Estimation of fm and FG Values Directly from Clinical Drug-Drug Interaction Study Data
Yumi Cleary, Nicolo Milani, Kayode Ogungbenro, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
December 13, 2005
Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial
Marylore Chenel, Kayode Ogungbenro, Vincent Duval, et al.
Pharmaceutical Research
|
November 27, 2014
Model-based evaluation of the impact of formulation and food intake on the complex oral absorption of mavoglurant in healthy subjects
Thierry Wendling, Kayode Ogungbenro, Etienne Pigeolet, et al.
The AAPS Journal
|
November 6, 2015
Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data
Thierry Wendling, Nikolaos Tsamandouras, Swati Dumitras, et al.
The AAPS Journal
|
December 16, 2015
Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions
Alison Margolskee, Adam S Darwich, Aleksandra Galetin, et al.
The AAPS Journal
|
April 29, 2025
Simultaneous Estimation of fm and F<sub>G</sub> Values Directly from Clinical Drug-Drug Interaction Study Data
Yumi Cleary, Nicolo Milani, Kayode Ogungbenro, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
March 22, 2006
Optimal design for multivariate response pharmacokinetic models
Ivelina Gueorguieva, Leon Aarons, Kayode Ogungbenro, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
March 5, 2021
Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexed
Aurélie Lombard, Hitesh Mistry, Sonya C Chapman, et al.
British Journal of Clinical Pharmacology
|
August 24, 2017
Population pharmacokinetics of the MEK inhibitor selumetinib and its active N-desmethyl metabolite: data from 10 phase I trials
Parul Patel, Eleanor Howgate, Paul Martin, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
December 3, 2014
Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model
Andrés Olivares-Morales, Yoshiteru Kamiyama, Adam S Darwich, et al.
Page
of 13